162 related articles for article (PubMed ID: 38331878)
1. Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
Li Y; Su H; Liu K; Zhao Z; Wang Y; Chen B; Xia J; Yuan H; Huang DS; Gu Y
World J Surg Oncol; 2024 Feb; 22(1):49. PubMed ID: 38331878
[TBL] [Abstract][Full Text] [Related]
2. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
[TBL] [Abstract][Full Text] [Related]
5. T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
Eryilmaz IE; Kordan Y; Vuruskan BA; Kaygısız O; Tunca B; Cecener G
Gene; 2018 Mar; 645():69-75. PubMed ID: 29277318
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
7. Colorimetric TMPRSS2-ERG Gene Fusion Detection in Prostate Cancer Urinary Samples via Recombinase Polymerase Amplification.
Koo KM; Wee EJ; Trau M
Theranostics; 2016; 6(9):1415-24. PubMed ID: 27375789
[TBL] [Abstract][Full Text] [Related]
8. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
9. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
10. RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
Eryilmaz IE; Aytac Vuruskan B; Kaygısız O; Egeli U; Tunca B; Kordan Y; Cecener G
Prostate; 2019 Feb; 79(2):195-205. PubMed ID: 30294801
[TBL] [Abstract][Full Text] [Related]
11. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
Mancarella C; Casanova-Salas I; Calatrava A; Ventura S; Garofalo C; Rubio-Briones J; Magistroni V; Manara MC; López-Guerrero JA; Scotlandi K
Oncotarget; 2015 Jun; 6(18):16611-22. PubMed ID: 25906745
[TBL] [Abstract][Full Text] [Related]
12. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
[TBL] [Abstract][Full Text] [Related]
13. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY
J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747
[TBL] [Abstract][Full Text] [Related]
14. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
15. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical application of
Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Luedeke M; Rinckleb AE; FitzGerald LM; Geybels MS; Schleutker J; Eeles RA; Teixeira MR; Cannon-Albright L; Ostrander EA; Weikert S; Herkommer K; Wahlfors T; Visakorpi T; Leinonen KA; Tammela TLJ; Cooper CS; Kote-Jarai Z; Edwards S; Goh CL; McCarthy F; Parker C; Flohr P; Paulo P; Jerónimo C; Henrique R; Krause H; Wach S; Lieb V; Rau TT; Vogel W; Kuefer R; Hofer MD; Perner S; Rubin MA; Agarwal AM; Easton DF; Al Olama AA; Benlloch S; ; Hoegel J; Stanford JL; Maier C
Hum Mol Genet; 2016 Dec; 25(24):5490-5499. PubMed ID: 27798103
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
20. Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer.
Li C; Zhang J; Wu Q; Kumar A; Pan G; Kelvin DJ
Mol Cancer Ther; 2023 Mar; 22(3):306-316. PubMed ID: 36622760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
